{"name":"Salubris Biotherapeutics Inc","slug":"salubris-biotherapeutics-inc","ticker":"","exchange":"","domain":"salubrisbiotherapeutics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNdXdDbzlSaVZSYU5yLS15QnRLcDU4bWgtRG1HaWxWYncteVYwbTdCU2YycTZfa0Z1ZFp0T25mREJaZ1N0ZkU5YVptRndDTW9SNi1IcUpIYWVpNHU1TmF5OTJpdklCUldXRVFtVjFIZDFiVDM4Ml9kam02VmdRRzc4QXJqS0dYRW0tN1pMLU9zdUlILUlmbUx4Y2NlQmtnOGlTamVTUXVtRUNyQlNKSkZPNmFZd1hrc3dHdjZpTUJxMWNPa0p1aHpLOGlhOVVHSEg0a21WRzdDb1NTUEFiS29xZ0l2dVFCOS1OdXdoYjhVU0plczRod2N4Z2NnNHFONGYteXFINnNKc1N5bEgteXdnV0htMTNzQ3R1TnVsY0lzQkx6d1BvZy1RTGdB?oc=5","date":"2025-10-20","type":"trial","source":"BioSpace","summary":"Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress - BioSpace","headline":"Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the Europea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOUEcwVXpRWUZYZ0E3djJ6TDBwUEtZMzdGQVF5UDQtTXd3VVpwRWZhNl9EMzBHcTR6dEJsSDYwcWZwUXFnOWxONGhRUWtFWTVrNGJlMjE4QUI2dy0weU01SS1KeXRLelhBTEpGMi1RczM0N2VjOU41b05mNjNRTGRJWUtGTFpLWlVsanNpVUMtbms3bGhYamIyeFpVVVhsbjBZSTBUM2g0eEktRFJ2SVMxTC04MUkwZzA?oc=5","date":"2025-09-29","type":"pipeline","source":"BioSpace","summary":"Salubris Biotherapeutics Provides Updates on JK07 and JK06 Clinical Programs - BioSpace","headline":"Salubris Biotherapeutics Provides Updates on JK07 and JK06 Clinical Programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPVExmc015Z2JrLXpSV0IyTkJJbl96bHpSREN2endMUEZlZDhXaHRWSVR0aEJxRTNac0M0UVlQZU1yU3Y2WHNGbGZaR2ljeGQxYm5IWEZpcVZpclZuRmtBSDcyZDJKaXBXSVdGVDJhb2FueXF3T3lIZ0RqekZzeEE2dFZIbTdISGhOYUljcENsaU5KdzQzUGlKYkRLT0xpLWxHY1RobHFOQ3ozMlNWWkp2M1lZNlJNaFppTjRZaDZONGV3czBTcnBDenFtYjVrTENJQkx5eWZIM3ZDaGFVd1RkTm1LX3gtOEVxelpnajY4cEItTms?oc=5","date":"2025-01-22","type":"trial","source":"businesswire.com","summary":"Salubris Biotherapeutics Announces Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure - businesswire.com","headline":"Salubris Biotherapeutics Announces Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxPWGxZZ1NMTzltX0hmdzBRMjFrXzZINzhUdDQ3VW5oN0JHNUpoQzBwMjJTRWxWRHVLVHJBWVJESVp1aUs1YWNvZUdjaHZFSWtYNDR1YTBMc0M3YkMtdFQ2c2hSNWlwUnNUWWFYX0VwN0pKb2pkWjY0RFJqVk8zTUlEMlJmZVNrZXRYdXYzdUd3TnNqWTllNGFrUWo1YmNMVEgxNTI1MlJ2MGstZERpaVBKUnVtYzk5RHZhME9oZHlkdWNUNDZ2NGM5QW1XeW9TZHZtRW1iWTRhM0c1NVRWUDJpZUMzRGI3TUdoQThVQkNHRldSZjMydEJZa1RyTHhyUGFNNVFnMnl0ZlJkWVNCNGVSeE9KZ2pHLS05WWl0WmRfR3NXelhYMEJFNllqVVUxSzA?oc=5","date":"2024-08-05","type":"regulatory","source":"businesswire.com","summary":"Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of JK06, a 5T4-Targeted ADC, in Solid Tumors - businesswire.com","headline":"Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of JK06, a 5T","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOanpqaUpIQy0zMlRWNFFRcnV4LXlmT0ZTQlU1S3N5c29BdkpiSVZ3b3RMTFIyeFFnRUxDd2s0TXVqVGVhZmo2NzJjeXR6Y0NfMGhOTkI1SkFnMFF6ZGw0MjFsQmx0aEg3RHVKV2o2MGpPQlVJNmRJOGtxSDZGaGh2QmNybXlOLUJia0QySk9McVBnVWRObk9QdEZLRnN4NVlYa1ItaFZ4OHkzclYyWHFFZTNDajlJbWJrZmRQV3JNc2lkaktUVFpQdTdQejFwVjdFUmJ2LXFvX2JPSkVzZnNsVnlkV0xOX0FVcC03Uw?oc=5","date":"2024-04-22","type":"pipeline","source":"businesswire.com","summary":"Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update - businesswire.com","headline":"Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxOLVhMam5aQ2psdndDSms1REpvVnl1NFlNZjEwbkFCc0Z0a01oYzVWNFJid2EzRU53SEF5cFRGa3lDTlRsd0cwaHFra014WVZjUmVHbU1Ec3dWMGJETGxaUVFUYW5tWUJGWkJuOEk0NDhLNlpLUUR5aUItdE9CT3ljMnpNM1BJQlNxSW8yX2VHdGNZeGl3UVptTVN4cmNRTGMyTnpXZU1LQjVRc0ZSd3FRTWJ5dXR0WXNFQ1YyT3RpMzZWd19rcnJzcWdLTzB2YmFJekJmQkdiVXQ2NEtXOEdGc0p1YW04NUJ2eF84bUFpNWU2R2piSlZ2Mm1RS1hOT3A3bC1PcDVNWlY0UTQ?oc=5","date":"2023-03-28","type":"pipeline","source":"businesswire.com","summary":"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates - businesswire.com","headline":"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQalNTVHcycUljd1I1a2JBVzRubkVSY1pwZXJ4b3BleU5lWHd5Nk1KM05QaEt0VE4xN1JZa28wY0N6aEc1RVp0OU4xZDMwajJxdm5RWHVFMkZteUtKMTZmaFZiZWp4c1N0WkNVUjJmTXB6bUtpOVFqa05TRENoQlVVQnU1Sm9XLWNZRXVUVDJhWjQycktnWElmNUE4ZlNqaVBvLUhmaHVlLUJKejZqcVF1SVln?oc=5","date":"2022-05-23","type":"pipeline","source":"citybiz","summary":"Salubris Biotherapeutics Appoints Arian Pano, M.D., as Chief Medical Officer - citybiz","headline":"Salubris Biotherapeutics Appoints Arian Pano, M.D., as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxORlJTM3FTNExqcmZQNUlmOVRZYW9XWnJ5OS1lblp4U3JFV0pMMXR1Y3k5YUZDQmlXR3RBQ1pRR05heGhKSFliWXRhMkRqUEdyZEpzVzFaOEVYdjU1dFVQcFE0cnplZjFBaXBYblcwQW1WRzBBa2Y5ZWttV0ludVNkb0o5UzJYbjdBc0pXSldpdzlEaFl4YlM5YkVOMWhkTjNBclg2MHhGeG1tYk9yUzZVbzZmWFBrb0lDbE5BZlVtMmp6YktURThMMFN1YnRKd3N0RUt0UmVnVTVGaGh6TkNVS1dIWU12UlFuc2Q0R3VIWXlUbm93d3M3M0o5c3pUWjNsd25QMEhaaGFFVWhOS1J6dzRVOVRDZUpxWmRDVVJwaEI?oc=5","date":"2022-03-09","type":"pipeline","source":"The MoCo Show -","summary":"Gaithersburg: Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases - The MoCo Show -","headline":"Gaithersburg: Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovasc","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2017-08-09","type":"pipeline","source":"huffpost.com","summary":"The U.S. Is Quietly Giving A Chinese Billionaire A Monopoly On A Cancer Drug - huffpost.com","headline":"The U.S. Is Quietly Giving A Chinese Billionaire A Monopoly On A Cancer Drug","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}